Drug Interaction Report

GENERALLY AVOID: Coadministration with ceftobiprole may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporting polypeptide (OATP) 1B1 and/or OATP1B3. The proposed mechanism is decreased clearance due to ceftobiprole-mediated inhibition of OATP1B1 and/or OATP1B3.

MANAGEMENT: Concomitant use of ceftobiprole with drugs that are substrates of OATP1B1 and/or OATP1B3 is not recommended. Clinical and laboratory monitoring may be appropriate whenever ceftobiprole is added to or withdrawn from therapy with these drugs. Dosage adjustments may be considered if an interaction is suspected. Patients should be monitored for the development of adverse effects.

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.